SCHEDULE: Evogene Faces Shareholder Activism Over Performance

L.I.A. Pure Capital and Invest-Pro criticize Evogene's track record and urge shareholders to vote for their board nominees.

Summary

• L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd. (collectively, the 'Reporting Persons') have filed an amendment to their Schedule 13D, reporting their communication to Evogene Ltd. shareholders dated August 28, 2026.
• This communication, titled 'Response of L.I.A. Pure Capital and Invest-Pro to Evogene's August 25, 2026 Press Release,' expresses dissatisfaction with Evogene's historical performance, governance, and board composition.
• The Reporting Persons are encouraging shareholders to support their nominees for election to the Evogene board at the upcoming annual meeting.
• They argue that despite years of pursuing evolving strategies and investing heavily, the company has a track record of limited commercial realization and significant erosion of shareholder value.
• The Reporting Persons contend that board refreshment should be measured by outcomes, not just headcount, and that experience alone does not create shareholder value if it hasn't translated into results.
• The filing indicates that as of July 27, 2026, the Reporting Persons collectively beneficially owned 3,057,488 shares of Evogene, representing 19.35% of the outstanding ordinary shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the strong criticism of the company's past performance and governance by activist shareholders.

Negatives

• Shareholders have been asked to remain patient for years while the company pursued evolving strategies and invested heavily, but there has been limited commercial realization.
• Significant erosion of shareholder value has occurred over the years.
• The company has repeatedly promised long-term value creation but has failed to deliver.
• Despite recent board additions, the company's performance trajectory has not materially improved.
• The incumbent board's experience has not translated into positive results for shareholders.

Risks

• Continued shareholder dissatisfaction could lead to a proxy fight and instability.
• The company's ability to attract and retain shareholder support for its strategic direction may be impacted.
• Potential for ongoing disputes regarding board composition and company strategy.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company itself, but rather expresses the Reporting Persons' views on the company's past performance and their intentions regarding board composition.

Management Comments

• "The Question Is Not What We Have Promised- It Is What the Company Has Delivered"
• "For years, shareholders have been asked to remain patient while the Company pursued evolving strategies, invested heavily in technology, raised funds while diluting existing shareholders and repeatedly promised long-term value creation. Yet the Companys track record tells a different story- years of limited commercial realization and significant erosion of shareholder value."
• "The fundamental question is not whether L.I.A. Pure Capital and Invest-Pro can guarantee future outcomes, but whether the incumbent Boards record warrants continued confidence."
• "After years of shifting strategies and promised value creation, the Company has failed to translate its scientific capabilities and investments into meaningful commercial results, while shareholders have suffered significant erosion in value."
• "Shareholders should judge the incumbent Board by its record- not by its promises."
• "Refreshment should be measured by outcomes, not headcount. Despite these changes, the Companys performance trajectory has not materially improved."
• "Experience Alone Does Not Create Shareholder Value... The issue is not the length of resumes, but whether that experience has translated into results."
• "After years of underperformance, shareholders deserve a board judged by results, not intentions."

Industry Context

StockSavvy.ai notes that shareholder activism is a recurring theme in the biotechnology and technology sectors, where long development cycles and significant capital investment can lead to periods of underperformance and shareholder frustration. Companies like Evogene, which have historically focused on R&D, often face scrutiny regarding their path to commercialization and capital efficiency.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the call for a vote on board nominees and the criticism of past performance, potentially leading to a proxy contest and influencing investment decisions.
• Management and Board: Facing direct challenge to their leadership and track record, with potential for changes in composition and strategy.
• Employees: May experience uncertainty regarding future company direction and leadership stability.

Next Steps

• Shareholders are urged to vote FOR the L.I.A. Pure Capital and Invest-Pro nominees at the upcoming annual meeting.
• The Reporting Persons intend to continue advocating for changes in board composition and company direction.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' as the filing highlights significant shareholder activism and concerns about past performance, suggesting potential for volatility and a proxy fight. While the criticism is strong, the outcome of the shareholder vote is uncertain, and the company's future strategic direction remains to be determined. Investors should monitor developments closely.

Keywords

Evogene, Schedule 13D, Shareholder Activism, Corporate Governance, Board Nominees, Proxy Fight, Shareholder Value, Investment Performance